LASA · NSE
Lasa Supergenerics Limited
₹6.52
-2.54% (-₹0.17)
Prev. close
₹6.69
Volume
46,913
Delivery %
88.6%
As of
09 Sept 2026
Price history
No analyst calls on this stock in the last 90 days yet.
Explore by date range →Analyst opinions
Fundamentals
About Lasa Supergenerics Limited
Lasa Supergenerics Limited engages in the research, manufacture, and marketing of animal and human healthcare products in India. It offers API bulk drug products comprising fenbendazole, toldimphos sodium, cyromazine, albendazole, ricobendazole, triciabendazole, oxfendazole, closantel base, closantel sodium dihydrate BP, nitroxynil, rafoxanide, oxyclozanide, ornidazole, halquinol, and 2,6-diiodo-4-nitrophenol; and other API products. The company also provides animal feed ingredients, including calcium iodate; and reagents for therapeutic use, such as potassium iodide. In addition, it exports its products. Lasa Supergenerics Limited was incorporated in 2016 and is based in Ratnagiri, India.
Details
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
CEO
Dr. Omkar Pravin Herlekar
Headquarters
Ratnagiri
Website
lasalabs.comExchange
View on NSE ↗Key stats
Market cap
₹32.67 Cr
EPS (TTM)
₹-3.29
Beta (1Y · daily vs NIFTY 50)
0.78
Beta (5Y · monthly vs NIFTY 50)
1.92
Shares float
1.90 Cr
EPS · quarter ended Jun 2026
₹-0.71
Financial Performance
01 · Financials
Revenue for Mar 2021–Mar 2022 is as filed with BSE (standalone), and the first plotted growth figure is computed against Mar 2020 revenue as filed with BSE; the two sources' revenue definitions differ by 0.0% on Mar 2023. FY21 growth needs FY20 filings, which the data source doesn't provide.
02 · Earnings Per Share (EPS)
03 · Dividend Profile
Growth compares completed fiscal-year dividend totals on the company's own calendar: April–March (Indian FY), taken from its reported period-ends. Payout ledger: NSE corporate actions.
04 · Operating Efficiency (Growth Rates)
Balance-sheet-based
05 · Capital Structure & Asset Utilization
Asset turnover needs a prior year of assets — omitted for the earliest available year.
06 · Asset Base Composition
07 · Debt Level & Coverage
08 · Profit & Loss
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹202.38 Cr | ₹137.13 Cr | ₹129.57 Cr | ₹104.34 Cr | ₹142.45 Cr | ₹25.14 Cr | |
| EBITDA | ₹47.28 Cr | ₹7.83 Cr | ₹-24.69 Cr | ₹-6.51 Cr | ₹-4.39 Cr | ₹-28.20 Cr |
| ₹22.78 Cr | ₹-5.37 Cr | ₹-38.62 Cr | ₹-21.73 Cr | ₹-14.76 Cr | ₹-34.09 Cr | |
| Diluted EPS | ₹5.6 | ₹-1.32 | ₹-7.71 | ₹-4.34 | ₹-2.95 | ₹-6.8 |
09 · Balance Sheet
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹208.00 Cr | ₹209.00 Cr | ₹164.00 Cr | ₹151.00 Cr | ₹102.00 Cr | ₹66.00 Cr | |
| — | — | ₹21.77 Cr | ₹22.08 Cr | ₹2.13 Cr | ₹9.75 Cr | |
| Stockholders' equity | ₹159.00 Cr | ₹158.00 Cr | ₹118.00 Cr | ₹97.00 Cr | ₹84.00 Cr | ₹50.00 Cr |
Current assets, Trade receivables, Cash & equivalents, Non-current assets, CWIP, Others, Total debt, Long-term debt, Current (short-term) debt have filed figures for only some of the years shown — the missing years are left blank rather than estimated.
Annual only — the data source doesn’t publish quarterly balance-sheet detail for most NSE-listed companies.
10 · Cash Flow Statement
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹41.31 Cr | ₹10.49 Cr | ₹-17.30 Cr | ₹1.83 Cr | ₹-2.88 Cr | ₹-7.37 L | |
| Investing cash flow | ₹-3.60 Cr | ₹-3.25 Cr | ₹11.19 Cr | ₹-39.78 L | ₹8.15 Cr | ₹0 |
| ₹-36.44 Cr | ₹-4.03 L | ₹4.16 Cr | ₹-1.93 Cr | ₹-5.66 Cr | ₹0 | |
| Capital expenditure | ₹-6.59 Cr | ₹-2.28 Cr | ₹-4.83 Cr | ₹-1.66 Cr | — | — |
| End cash position | ₹3.84 Cr | ₹11.07 Cr | ₹79.95 L | ₹60.81 L | ₹27.53 L | ₹28.78 L |
Debt issued, Debt repaid, Capital expenditure have filed figures for only some of the years shown — the missing years are left blank rather than estimated.
Annual only — the data source has no quarterly cash-flow-statement coverage.
11 · Shareholding Pattern
NSE, quarterly
| Line item | Sep 21 | Dec 21 | Mar 22–Dec 22(4Q) | Jan 23–Mar 26(14Q) |
|---|---|---|---|---|
| Promoter | 64.47% | 45.01% | 43.78% | 53.65% |
| Public | 35.53% | 54.99% | 56.22% | 46.35% |
| Employee trusts | 0.00% | 0.00% | 0.00% | 0.00% |
Source: NSE quarterly shareholding-pattern filings, collapsed to periods where the reported percentages held steady — a column spanning several quarters means no change was filed across them. No FII/DII sub-split available from this source — Public includes all non-promoter, non-employee-trust holders.
12 · Peer Comparison
Healthcare
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4.48 L Cr | ₹1,846.4 | 37.1 | 5.37 | 13.7% | 0.06 | +11.9% | +12.3% |
| Divi's Laboratories Limited | ₹2.49 L Cr | ₹9,410.5 | 84.7 | 14.85 | 15.3% | 0.00 | +12.3% | +51.8% |
| Torrent Pharmaceuticals Limited | ₹1.84 L Cr | ₹4,970 | 77.5 | 21.95 | 25.8% | 1.79 | +21.5% | +36.9% |
| Apollo Hospitals Enterprise Limited | ₹1.28 L Cr | ₹8,835.5 | 61.5 | 13.52 | 20.5% | 0.90 | +15.7% | +14.2% |
| Lenskart Solutions Limited | ₹1.18 L Cr | ₹691.45 | 179.0 | 13.55 | 5.6% | 0.35 | +35.4% | — |
| Zydus Lifesciences Limited | ₹1.16 L Cr | ₹1,161 | 25.8 | 4.27 | 18.6% | 0.46 | +18.4% | +11.9% |
| Cipla Limited | ₹1.12 L Cr | ₹1,384.1 | 33.2 | 3.25 | 11.3% | 0.02 | +2.1% | -10.3% |
| Laurus Labs Limited | ₹1.09 L Cr | ₹2,006.5 | 99.3 | 20.57 | 16.8% | 0.48 | +22.0% | +122.0% |
| Max Healthcare Institute Limited | ₹1.02 L Cr | ₹1,066.6 | 70.4 | 9.50 | 13.4% | 0.32 | +19.0% | -8.0% |
| Manipal Health Enterprises Limited | ₹99,047.90 Cr | ₹746.1 | 152.1 | 11.75 | 7.8% | 1.53 | +18.0% | — |
| Dr. Reddy's Laboratories Limited | ₹98,709.15 Cr | ₹1,198.3 | 29.8 | 2.62 | 11.4% | 0.21 | +3.2% | -9.3% |
| Lasa Supergenerics Limited | ₹32.67 Cr | ₹6.52 | — | 0.66 | -68.7% | 0.20 | -82.4% | -52.0% |
Ranked by market cap within Healthcare, same metrics as the Fundamentals screener. Click a column to sort.
Documents
Annual reports
Concall transcripts
Official documents linked from their sources — offer documents as filed with SEBI (sebi.gov.in), annual reports and earnings-call transcripts as published on BSE (bseindia.com) and NSE (nseindia.com). Links open the source's own hosting; nothing is re-hosted here.